By admin 
In a decisive move to address the stagnant survival rates of pediatric bone cancer, CureSearch for Children’s Cancer has announced a major funding initiative directed toward the David Geffen School of Medicine at UCLA. The project, led by Dr. John Lee, an associate professor in residence in the Division of Hematology/Oncology, focuses on a novel application of chimeric antigen receptor (CAR) T-cell therapy specifically designed to combat metastatic Ewing sarcoma. This research is backed by an investment exceeding $900,000 through the CureSearch Acceleration Initiative Award, a program designed to bridge the gap between laboratory discovery and clinical application for pediatric patients.
Ewing sarcoma represents the second most common bone malignancy in children and young adults. While localized cases have seen improvements in outcomes over the past several decades, the prognosis for patients with metastatic or recurrent disease remains catastrophic. Current data indicates that the five-year survival rate for children with advanced Ewing sarcoma can be as low as 15%, a figure that has shown little significant improvement despite advancements in surgical techniques and traditional chemotherapy. Dr. Lee’s research represents a shift toward precision immunotherapy, aiming to provide a more targeted and less toxic alternative to the intensive regimens currently in use.
The Pathogenesis and Challenges of Ewing Sarcoma
Ewing sarcoma is characterized by a specific genetic translocation, most commonly the fusion of the EWSR1 gene on chromosome 22 to the FLI1 gene on chromosome 11. This fusion creates an abnormal protein that acts as a transcription factor, driving the uncontrolled growth of cancer cells. Despite knowing the genetic driver of the disease, developing targeted therapies has proven difficult because the EWS-FLI1 protein is notoriously "undruggable" with traditional small-molecule inhibitors.
Furthermore, metastatic Ewing sarcoma presents a unique challenge to the immune system. Solid tumors like Ewing sarcoma often create an immunosuppressive microenvironment that prevents the body’s natural T-cells from identifying and attacking malignant cells. When the cancer spreads to the lungs or other bones, the complexity of the disease increases, often rendering standard treatments like radiation and high-dose chemotherapy ineffective or overly debilitating for young patients. The urgency for a biological breakthrough is underscored by the high relapse rate and the long-term toxicity associated with current "slash, burn, and poison" methods of treatment.
Innovation in Immunotherapy: The Role of IL-18 and CAR T-Cells
Dr. John Lee’s research at UCLA centers on the evolution of CAR T-cell therapy. This technology involves harvesting a patient’s own T-cells, genetically engineering them to recognize specific proteins on the surface of cancer cells, and then reintroducing them into the patient’s bloodstream to seek and destroy the tumor. While CAR T-cell therapy has seen remarkable success in treating liquid cancers such as certain types of leukemia and lymphoma, its efficacy in solid tumors has been limited.
The primary hurdle in treating solid tumors with CAR T-cells is "T-cell exhaustion," where the engineered cells lose their potency before they can fully eradicate the tumor. Dr. Lee’s team is addressing this by incorporating Interleukin-18 (IL-18), a potent pro-inflammatory cytokine, into the CAR T-cell architecture. This "armored" CAR T-cell approach is designed to not only target the Ewing sarcoma cells but also to bolster the surrounding immune response.
By secreting IL-18 directly within the tumor microenvironment, these modified T-cells can potentially overcome the suppressive signals sent by the cancer. IL-18 is known for its ability to stimulate natural killer (NK) cells and enhance the proliferation of other T-cells, creating a synergistic effect that amplifies the body’s overall anti-tumor activity. This dual-action mechanism—direct targeting combined with localized immune stimulation—is the cornerstone of Dr. Lee’s preclinical work, offering a glimmer of hope for achieving durable remissions in patients who have exhausted all other options.
The Acceleration Initiative: A Timeline for Clinical Impact
The funding provided by CureSearch is part of its Acceleration Initiative, a strategic model that prioritizes projects with a high probability of reaching clinical trials within a three-year timeframe. Unlike traditional academic grants that may fund basic science for decades without a clear path to the bedside, the Acceleration Initiative is outcome-oriented. It specifically targets the "Valley of Death" in drug development—the phase where promising laboratory results often stall due to a lack of funding for the rigorous testing required by the FDA.
The timeline for Dr. Lee’s project is aggressive. The initial phase involves the refinement of the CAR T-cell constructs and extensive preclinical testing in laboratory models to ensure both safety and efficacy. Following this, the research will move toward the production of clinical-grade cells and the filing of an Investigational New Drug (IND) application. The goal is to begin enrolling pediatric patients in a Phase I clinical trial by the end of the three-year funding cycle. This rapid transition is essential for children currently battling metastatic disease, for whom time is the most precious resource.
A Collaborative Funding Model and the Legacy of Patients
The $900,000 grant is the result of a collaborative funding effort, highlighting a growing trend in the non-profit sector where organizations pool resources to maximize impact. The award is supported in part by the Rally Foundation for Childhood Cancer Research and three CureSearch Legacy Funds: The Garret Collins Legacy Fund, The Nick Currey Fund, and The Sam Schneider Legacy.
These legacy funds are established by families who have lost children to cancer, turning personal tragedy into a catalyst for scientific progress. The stories of Garret, Nick, and Sam serve as a poignant reminder of the stakes involved in this research. For the family of Sam Schneider, the project is a way to honor Sam’s wish to raise awareness for a disease that is often diagnosed too late. For Nick Currey’s family, the focus is on developing less toxic therapies, noting that the harshness of current treatments is often as damaging as the disease itself.
This human element adds a layer of accountability to the research. The involvement of legacy funds ensures that the scientific community remains connected to the primary goal: saving the lives of children and improving the quality of life for survivors. The collaboration between UCLA, CureSearch, and these family-led foundations represents a unified front against a disease that has historically been underfunded compared to adult cancers.
Broader Implications for Pediatric Oncology
The implications of Dr. Lee’s work extend beyond Ewing sarcoma. If the "armored" CAR T-cell approach utilizing IL-18 proves successful in bone cancer, it could serve as a blueprint for treating other recalcitrant pediatric solid tumors, such as osteosarcoma or neuroblastoma. The strategy of modifying the tumor microenvironment through cytokine secretion is a burgeoning field in oncology, and this project places pediatric research at the forefront of that innovation.
Furthermore, the focus on precision medicine aligns with the broader shift in oncology toward therapies that minimize collateral damage to healthy tissues. Traditional chemotherapy does not distinguish between rapidly dividing cancer cells and healthy cells, leading to the severe side effects—including secondary cancers, heart damage, and infertility—that plague childhood cancer survivors. By training the immune system to recognize specific markers on Ewing sarcoma cells, Dr. Lee’s team is working toward a future where "cure" does not come at such a high physical cost.
Fact-Based Analysis of the Pediatric Research Landscape
While the funding of Dr. Lee’s project is a significant milestone, it also highlights the systemic challenges in pediatric cancer research. Only a small fraction of federal cancer research funding is dedicated to pediatric-specific diseases, with the vast majority directed toward adult cancers like breast, lung, and prostate. This disparity makes the role of private foundations like CureSearch and the Rally Foundation critical.
The success of the Acceleration Initiative Award depends on its ability to attract follow-on investment from the pharmaceutical industry once the initial clinical data is generated. By de-risking the early stages of development through philanthropic support, these grants make pediatric drug development more attractive to commercial partners. Dr. Lee’s work at UCLA is a vital link in this chain, providing the scientific foundation necessary to bring 21st-century medicine to one of the most vulnerable patient populations.
As the project moves forward, the medical community will be watching closely. The integration of IL-18 into CAR T-cell therapy represents a sophisticated leap in bioengineering. If the preclinical promises translate into clinical success, it will not only change the prognosis for metastatic Ewing sarcoma but will also validate a new methodology for treating solid tumors across the spectrum of pediatric oncology. For now, the focus remains on the laboratory at UCLA, where the next three years could redefine the standard of care for children who currently face a 15% survival rate.
